From Wikipedia, the free encyclopedia
Chemical compound
Firibastat
![](https://upload.wikimedia.org/wikipedia/commons/thumb/6/66/Firibastat.svg/220px-Firibastat.svg.png) |
|
Other names | QGC-001 |
---|
|
Legal status |
|
---|
|
(3S,3′S)-4,4′-Disulfanediylbis(3-amino-1-butanesulfonic acid)
|
CAS Number | |
---|
PubChem
CID | |
---|
DrugBank | |
---|
ChemSpider | |
---|
UNII | |
---|
ChEMBL | |
---|
|
Formula | C8H20N2O6S4 |
---|
Molar mass | 368.50 g·mol−1 |
---|
3D model (
JSmol) | |
---|
C(CS(=O)(=O)O)[C@@H](CSSC[C@H](CCS(=O)(=O)O)N)N
|
InChI=1S/C8H20N2O6S4/c9-7(1-3-19(11,12)13)5-17-18-6-8(10)2-4-20(14,15)16/h7-8H,1-6,9-10H2,(H,11,12,13)(H,14,15,16)/t7-,8-/m0/s1 Key:HJPXZXVKLGEMGP-YUMQZZPRSA-N
|
Firibastat is a
prodrug of two
brain aminopeptidase A inhibitors, developed to treat
resistant hypertension.
[1]
[2]
[3]
[4] It failed to show efficacy in a Phase III trial.
[5]
References
-
^ Ojha, Utkarsh; Ruddaraju, Sanjay; Sabapathy, Navukkarasu; Ravindran, Varun; Worapongsatitaya, Pitchaya; Haq, Jeesanul; Mohammed, Raihan; Patel, Vinod (2022).
"Current and Emerging Classes of Pharmacological Agents for the Management of Hypertension". American Journal of Cardiovascular Drugs. 22 (3): 271–285.
doi:
10.1007/s40256-021-00510-9.
ISSN
1175-3277.
PMC
8651502.
PMID
34878631.
-
^ Ferdinand, Keith C.; Balavoine, Fabrice; Besse, Bruno; Black, Henry R.; Desbrandes, Stephanie; Dittrich, Howard C.; Nesbitt, Shawna D. (9 July 2019).
"Efficacy and Safety of Firibastat, A First-in-Class Brain Aminopeptidase A Inhibitor, in Hypertensive Overweight Patients of Multiple Ethnic Origins: A Phase 2, Open-Label, Multicenter, Dose-Titrating Study". Circulation. 140 (2): 138–146.
doi:
10.1161/CIRCULATIONAHA.119.040070.
ISSN
0009-7322.
PMID
31014072.
S2CID
129943816.
-
^ Hansen, Emma; Grimm, Daniela; Wehland, Markus (27 January 2022).
"Current Knowledge about the New Drug Firibastat in Arterial Hypertension". International Journal of Molecular Sciences. 23 (3): 1459.
doi:
10.3390/ijms23031459.
ISSN
1422-0067.
PMC
8836050.
PMID
35163378.
-
^ Alomar, Sara Abdulrahman; Alghabban, Sarah Ali; Alharbi, Hadeel Abdulaziz; Almoqati, Mehad Fahad; Alduraibi, Yazid; Abu-Zaid, Ahmed (5 January 2021).
"Firibastat, the first-in-class brain aminopeptidase a inhibitor, in the management of hypertension: A review of clinical trials". Avicenna Journal of Medicine. 11 (1): 1–7.
doi:
10.4103/ajm.ajm_117_20.
ISSN
2231-0770.
PMC
7839263.
PMID
33520782.
-
^
"First-in-class aminopeptidase-A inhibitor fails to reduce treatment-resistant hypertension". Scientific Sessions. 9 November 2022. Retrieved 8 November 2023.